Nosocomial infections in critically ill Covid-19 patients

Abstract

Nosocomial infections follow the medical practice as a shadow, being present in medical systems worldwide, even in high-performance ones, being a public health problem because it is due to germs resistant to antimicrobials. In the critically ill Covid 19 patient, assisted in the intensive care units, where is subjected to invasive procedures, nosocomials become life-threatening. In 2021, 586 severe and critical Covid_19 cases were treated, the prevalence of nosocomiality being 10.23%. At a severe Covid 19 fatality rate was 70.72%, and reached 88.33% in health-care associated infections. Acinetobacter baumanii and Klebsiella pneumoniae, resistant to cephalosporins, aminoglycosides, quinolones, carbapenems and even polymyxin b, were frequently involved, identified especially in tracheobronchial secretions, Odds ratio for antimicrobial resistance being 4.3929 compared to other specimens (P = 0.015). It turns out that empirical antibiotic therapy, asepsis and antisepsis in intensive care need to be reconsidered.